| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Mark L Pacala is Director at TOIIW, with reported holdings spanning 2 companies. Mark L Pacala's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Mark L Pacala has 9 Form 4 filings on record from November 2022 to July 2026, across 2 companies: Director at The Oncology Institute (TOIIW), 2026; Director at Oncology Institute (TOI), 2022–2025.
The 15 reported transactions were 8 stock awards, 3 open-market sales, 2 open-market purchases and 2 other transactions.
Counted by filing, the open-market trades come to 1 purchase worth about $94K and 1 sale worth about $200K.
The only open-market purchase was 90,562 shares of TOI at an average $1.04 on March 26, 2025, about $94K. Twelve months later TOI was up 156%.
The only open-market sale was 50,000 shares of TOI at an average $4.00 on November 18, 2025, about $200K.